NEW YORK, May 24 (GenomeWeb News) - GE Healthcare signed an exclusive distribution agreement with DiscoveRx for its HitHunter cAMP assays, GE Healthcare said today.
Terms of the deal call for GE to exclusivelty distribute DiscoveRx's HitHunter cAMP Enzyme Fragment Complementation-based assays worldwid. The deal also expands GE's rights to distribute DiscoveRx's portfolio of kinase assays, with exclusive distribution in the Asia-Pacific region.
The cAMP assays are designed for high throughput, non-radioactive screening of compounds in drug discovery. The homogeneous cell-based assays are used to screen for G-protein coupled receptor activation in a microplate-based format.
Financial details were not disclosed.